



ImmunityBio Corporate Overview

Updated March 2021

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. These forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to ImmunityBio. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) potential adverse effects or changes to relationships with employees, suppliers or other parties resulting from the announcement or completion of the proposed transaction, (ii) the outcome of any legal proceedings that may be instituted against the parties and others related to the merger, (iii) unexpected costs, charges or expenses resulting from the merger, (iv) uncertainty of the expected financial performance of the combined company following completion of the merger, including the possibility that the expected synergies and value creation from the merger will not be realized or will not be realized within the expected time period, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs, and the timing and success of any such continued preclinical and clinical development and planned regulatory submissions, (vi) inability to retain and hire key personnel, and (vii) the unknown future impact of the COVID-19 pandemic delay on certain clinical trial milestones and/or ImmunityBio’s operations or operating expenses. More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in NantKwest’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC’s website at www.sec.gov. ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this presentation, except to the extent required by law.

ImmunityBio By the Numbers

17

First in Human
Molecules

25

Phase II / III
Clinical Trials

40

Phase I / II / III
Clinical Trials




2035+

Worldwide Patents Extending to
2035 and Beyond



400,000

Square Feet of Manufacturing and R&D Facilities




3 Trillion

3 Trillion Natural Killer Cells
Manufactured to Date

Antibody Cytokine
Fusion Proteins



Chemo Immuno
Modulators



Vaccine
Technologies



Natural Killer
Cells











Unparalleled Combined Immunotherapy Platforms



NASDAQ: IBRX



Unparalleled Combined Immunotherapy Platforms


	Antibody Cytokine Fusion Proteins	Albumin-Bound Immuno-Modulators	Vaccine Technologies	Natural Killer
Core Modalities	 <p>Activating NK & T Cells</p>	 <p>Tumoricidal Macrophages</p>	 <p>Memory T Cells</p>	 <p>Off-the-Shelf NK Cells Autologous Memory cNK</p>
Lead	Anktiva (N-803)	Aldoxorubicin	Adenovirus (hAd5)	Natural Killer (NK)
Mechanism of Action				

GMP Large Scale Adeno, Protein and Cell Therapy Manufacturing Capacity



QUILT Trials

Phase I / II Trials to Test the Hypothesis of Quantum Oncotherapeutics in Multiple Tumor Types



Quantum Oncotherapeutics

- Antibody Cytokine Fusion Proteins
- Albumin-Bound Immuno Modulators
- Natural Killer Cells
- Vaccine Vectors
- mAbs or CPIs

Testing the Hypothesis of Inducing Immunogenic Cell Death Through Exploratory Clinical Trials Across Multiple Tumor Types

Two (2) I/O Agents					
N-803	N-803	N-803	N-803	N-803	N-803
BCG	Rituximab	aNK	BCG	Pembro/Nivo	Pembro
1 st Line NMIBC Bladder	2 nd & 3 rd Line iNHL	2 nd & 3 rd Line Merkel Cell Carcinoma	2 nd Line NMIBC Bladder	3 rd Line Checkpoint Relapse NSCLC	1 st Line Metastatic NSCLC
QUILT-2.005	QUILT-3.002	QUILT-3.009	QUILT-3.032	QUILT-3.055	QUILT-2.023
Fast Track Phase 2*	Phase 1 / 2	Phase 2	Breakthrough Phase 2*	Pivotal Phase 2*	Pivotal Phase 2*
NCT02138734	NCT02384954	NCT02465957	NCT03022825	NCT03228667	NCT03520686

3 I/O Agents	
haNK	PD-L1 t-haNK
N-803	N-803
Avelumab	Aldoxorubicin
2 nd & 3 rd Line Merkel Cell Carcinoma	2 nd Line Metastatic Pancreatic Cancer
QUILT-3.063	spIND
Pivotal Phase 2*	spIND
NCT03853317	spIND

Five (5) I/O Agents	
Ad-CEA	Ad-CEA
Ye-Ras	Ye-Ras
aNK	haNK
N-803	N-803
Avelumab	Avelumab
2 nd & 3 rd Line Metastatic Pancreatic Cancer	2 nd & 3 rd Line Metastatic Pancreatic Cancer
QUILT-3.039	QUILT-3.060
Phase Ib / II	Phase Ib / II
NCT03136406	NCT03329248

Six (6) I/O Agents
Aldoxorubicin
Ad-CEA
Ye-Ras
aNK
N-803
Avelumab
2 nd & 3 rd Line Metastatic Pancreatic Cancer
QUILT-3.070
Phase Ib / II
NCT03387098

Ten (10) I/O Agents
Ad-MUC1
Ad-Brachy
Ye-Brachy
Ye-CEA
Aldoxorubicin
Ad-CEA
Ye-Ras
haNK
N-803
Avelumab
3 rd Line Metastatic TNBC
QUILT-3.067
Phase Ib / II
NCT03387085

Eleven (11) I/O Agents		
Ad-HER2	Ad-HER2	Ad-HER2
Ad-MUC1	Ad-MUC1	Ad-MUC1
Ad-Brachy	Ad-Brachy	Ad-Brachy
Ye-Brachy	Ye-Brachy	Ye-Brachy
Ye-CEA	Ye-CEA	Ye-CEA
Aldoxorubicin	Aldoxorubicin	Aldoxorubicin
Ad-CEA	Ad-CEA	Ad-CEA
Ye-Ras	Ye-Ras	Ye-Ras
haNK	haNK	haNK
N-803	N-803	N-803
Avelumab	Avelumab	Avelumab
3 rd Line Metastatic Head & Neck	3 rd Line Metastatic Randomized Colorectal	2 nd & 3 rd Line Metastatic Pancreatic Cancer
QUILT-3.090	QUILT-3.071	QUILT-3.080
Phase Ib / II	Phase Ib / II	Phase Ib / II
NCT03387111	NCT03563157	NCT03586869

May 2014 Mar 2015 Jun 2015 Jan 2017 Jul 2017 May 2018



Feb 2019 Sep 2019



May 2017 Nov 2017

Dec 2017

Dec 2017



Dec 2017 Jun 2018



Jul 2018



Unparalleled Combined Platforms: Solid Tumors (Oncology)

Solid Tumors	Phase	Target Indication	Preclinical	Ph I	Ph II	Ph III	Anktiva	Aldox	Vectors	NK Cells	
Bladder	II / III	BCG Unresponsive NMIBC Carcinoma In-Situ (CIS)	Breakthrough & Fast Track				Anktiva				NCT03022825
	II	BCG Unresponsive NMIBC Papillary	Fast Track				Anktiva				NCT02138734
Lung	I / II	Advanced or Metastatic NSCLC Relapsed or Refractory Checkpoint	Single Arm CPI Relapsed, Phase 1/2, Lung				Anktiva				NCT02523469
	II	2L or Greater Lung Cancer, Checkpoint Relapsed	Single Arm CPI Relapsed Basket, Phase 2, Lung				Anktiva			PD-L1 t-haNK	NCT03228667
	III	2L NSCLC Checkpoint Relapsed and Refractory LungMAP – S1800D (SWOG)	Randomized Phase 3, 2L Lung				Anktiva				Pending
	III	1L Squamous & Non-Squamous Non-Small Cell Lung Cancer Checkpoint Alone	Randomized Phase 3, 1L Lung Chemo Free				Anktiva				NCT03520686
	III	1L Non-Small Cell Lung Cancer Checkpoint + Concurrent Chemo	Randomized Phase 3, 1L Lung Chemo				Anktiva				NCT03520686
	I	Advanced Metastatic Pancreatic Cancer	Single Arm, Phase 1, Pancreatic				Anktiva	Aldox	hAd5-CEA, MUC1, Brachyury, HER2	haNK	NCT03586869
Pancreatic	II / III	3L Metastatic Pancreatic Cancer	Single Arm Phase 2, 3L Pancreas				Anktiva	Aldox		PD-L1 t-haNK	NCT04390399
	II / III	2L Metastatic Pancreatic Cancer	Randomized, Phase 2/3 2L Pancreas				Anktiva	Aldox		PD-L1 t-haNK	NCT04390399
	II / III	1L Metastatic Pancreatic Cancer	Randomized, Phase 2/3 1L Pancreas				Anktiva	Aldox		PD-L1 t-haNK	NCT04390399
Breast	I	3L or Greater Triple Negative Breast Cancer	Single Arm, Phase 1, 3L TNBC				Anktiva	Aldox	hAd5-CEA, MUC1, Brachyury	haNK	NCT03387085
	I / II / III	3L or Greater Triple Negative Breast Cancer	Randomized, Phase 1/2/3, 3L TNBC				Anktiva			PD-L1 t-haNK	Pending NCT
Colon	I	CEA Expressing Tumors	Single Arm, Phase 1, CEA				Anktiva		hAd5-CEA		NCT03127098
	II	3L Metastatic Colon Cancer	Single Arm, Phase 2, 3L Colon						hAd5-CEA		NCT01147965
	II	Metastatic or Unresectable Colon Cancer	Randomized, Phase 2, 2L or Greater Colon, NCI						hAd5-CEA		NCT03050814
Merkel	II	Recurrent Merkel Cell Carcinoma	Single Arm, Phase 2, Merkel				Anktiva			haNK	NCT03853317
Glioblastoma	II	Recurrent Glioblastoma	Single Arm, Phase 2, Glioblastoma					Aldox			NCT02014844
	I	Recurrent Glioblastoma	Single Arm, Phase 1, Glioblastoma, Frankfurt University							HER2 t-haNK	NCT03383978
Head & Neck	I	1L Recurrent & Neoadjuvant Head & Neck	Single Arm, Phase 1, Head & Neck, NCI				Anktiva		hAd5-CEA, MUC1, Brachyury		NCT04247282
Prostate	I / II	Castration Resistant Prostate Cancer Quick Efficacy Seeking Trial (QuEST1)	Randomized, Phase 1/2, Prostate, NCI				Anktiva				NCT03493945
	I	Castration Resistant Prostate Cancer	Single Arm, Phase I, Castration Resistant, NCI						hAd5-PSA, MUC1, Brachyury		NCT03481816
Ovarian	I	Advanced Ovarian Cancer – Intraperitoneal (IP) and/or Subcutaneous (SC) Alone	Randomized, Phase 1, Ovarian, University of Minnesota				Anktiva				NCT03054909
Sarcoma	I / II	Metastatic Soft Tissue Sarcoma Aldox + Ifosfamide	Single Arm, Phase 1 / 2, Sarcoma					Aldox			NCT02235701
	II	Advanced Soft Tissue Sarcoma Aldox vs Doxorubicin	Randomized, Phase 2, Sarcoma					Aldox			NCT01514188
	III	Metastatic, Locally Advanced Sarcoma	Randomized, Phase 3, Sarcoma					Aldox			NCT02049905
Advanced Solid Tumors	I	Multi-Targeted Recombinant Ad5 CEA, MUC1, Brachyury Vaccine Regimen in Adv. Cancer (NCI)	Single Arm, Phase 1, NCI						hAd5-CEA, MUC1, Brachyury		NCT03384316
	I	Advanced Solid Tumors, Yeast Neopeptide	Single Arm, Phase 1, Advanced Solid Tumors						Ye-NEO		NCT03552718
	I	Advanced Solid Tumors, M-ceNK	Single Arm, Phase 1, IND Filed							M-ceNK	Pending

Investigator Initiated Clinical Trial

Company Sponsored Clinical Trial

NMIBC – Non-Muscle Invasive Bladder Cancer, NCI – National Cancer Institute

Trial Completed

Unparalleled Combined Platforms: Liquid Tumors (Oncology)

Liquid Tumors	Phase	Target Indication	Preclinical	Ph I	Ph II	Ph III	Anktiva	Aldox	Vectors	NK Cells	
iNHL	I / II	Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma	Single Arm, Phase 1 / 2, iNHL				Anktiva				NCT02384954
Multiple Myeloma	I / II	Relapsed or Refractory Multiple Myeloma	Single Arm Phase 1 / 2, Multiple Myeloma				Anktiva				NCT02099539
	I	Multiple Myeloma & Lymphoma Relapse after Transplantation	Single Arm, Phase 1, Lymphoma & MM							aNK	NCT00990717
Lymphomas, AML, MDS	I	Hematological Malignancies Relapse After Allogenic Transplantation	Single Arm, Phase 1, Liquid Tumors				Anktiva				NCT01885897
	II	Adults w/ Relapsed or Refractory AML	Single Arm, Phase 2, AML				Anktiva				NCT03050216
	I	Acute Myeloid Leukemia & Lymphomas	Single Arm, Phase 1, AML & Lymphomas				Anktiva			Donor NK	NCT02890758
	II	Acute Myeloid Leukemia & Myelodysplastic Syndrome (MDS) Relapsed Prophylaxis	Single Arm, Phase 2, AML and MDS				Anktiva				NCT02782546
	I / II	Cytokine Induced Memory Like NK Cell After Hematopoietic Transplantation	Single Arm, Phase 1 / 2, AML				Anktiva			M-ceNK	NCT02989844
	I / II	Acute Myeloid Leukemia or Myelodysplastic Syndrome (MDS)	Single Arm, Phase 1 / 2, AML, MDS				Anktiva			M-ceNK	NCT01898793
	I	Diffuse Large B Cell Lymphoma	Single Arm, Phase 1, IND Authorized							CD-19 t-haNK	NCT04052061

■ Investigator Initiated Clinical Trial
 ■ Company Sponsored Clinical Trial
 ◆ Trial Completed

Unparalleled Combined Platforms: Infectious Diseases

Last Updated March 2021

Infectious Dis.	Phase	Target Indication	Preclinical	Ph I	Ph II	Ph III	Anktiva	Aldoxorubicin	Adenovirus	Natural Killer	
HIV	I	ACTG / NIAID: HIV Broadly Neutralizing Antibodies	Single Arm, Phase 1, HIV				✓ Anktiva				NCT04340596
	II	Thai Red Cross: Reducing HIV Persistence by IL-15	Randomized, Phase 2, HIV				✓ Anktiva				NCT04505501
COVID-19	I	COVID-19 Vaccine: hAd5 S+N USA (SC, SC)	Single Arm, Phase 1, COVID	Subcutaneous					✓ hAd5 S+N		NCT04591717
		COVID-19 Vaccine: hAd5 S+N USA (SC, SL)	Single Arm, Phase 1, COVID	Sublingual					✓ hAd5 S+N		NCT04591717
	I	COVID-19 Vaccine: hAd5 S+N USA (SC, Oral)	Single Arm, Phase 1, COVID	Oral Capsule					✓ hAd5 S+N		NCT04732468
	I	COVID-19 Vaccine: hAd5 S+N South Africa (SC, SC)	Single Arm, Phase 1, COVID	Subcutaneous					✓ hAd5 S+N		NCT04710303

Investigator Imitated Clinical TrialCompany Sponsored Clinical TrialTrial Completed